Cost-effectiveness of peginterferon α-2a and peginterferon α-2b combination regimens in genotype-1 naive patients with chronic hepatitis C

Hepato-Gastroenterology

Volumn 57, Issue 101, 2010, Pages 939-944

  Gheorghe, Liana ^a   Baculea, Simona ^b  

^a FUNDENI CLINICAL INSTITUTE   (Romania)

^b Roche Romania ^*  (Romania)

Author keywords

Cost effectiveness Peg IFN 2a; Genotype 1 chronic HCV infection

Indexed keywords

PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN;

ARTICLE; CLINICAL EVALUATION; COMPARATIVE STUDY; COST EFFECTIVENESS ANALYSIS; DRUG COST; GENOTYPE; HEPATITIS C; HUMAN; LIFE EXPECTANCY; MALE; NATIONAL HEALTH INSURANCE; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; ROMANIA; SENSITIVITY ANALYSIS; TREATMENT DURATION;

ANTIVIRAL AGENTS; COST-BENEFIT ANALYSIS; DRUG THERAPY, COMBINATION; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2A; INTERFERON ALFA-2B; MARKOV CHAINS; POLYETHYLENE GLYCOLS; QUALITY-ADJUSTED LIFE YEARS; ROMANIA; TREATMENT OUTCOME;

EID: 78149255106     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. WHO: Hepatitis C: global prevalence. Weekly Epidemiol Rec 2000; 75:18-22.
2. Shepard CW, Finelli L, Alter MJ: Global epidemiology of hepatitis C virus infection. Lancet Infect Dis 2005; 5:558-567.
3. Gheorghe L, Iacob S, Csiki IE: Prevalence of hepatitis C in Romania: Different from European rates. J Hepatology 2008; 49:661-662.
4. Grigorescu M, Radu C, Pascu O, et al: Etiological profile of chronic hepatitis and liver cirrhosis in Romania. A multicentre study. Rom J Gastroenterol 2001; 10:199-204.
5. EASL Consensus Conference on Hepatitis C: Consensus Statement. J Hepatol 1999; 30:956961.
6. Brown RS, Gaglo JP: Scope of worldwide hepatitis C problem. Liver Transpl 2003; 9:S10-S13.
7. National Institutes of Health Consensus Development Conference: Management of Hepatitis C - 2002. Hepatology 2003; 36 (Suppl 1):S3-S20.
8. Kjaergard LL, Krogsgaard K, Gluud C: Interferon alfa with or without ribavirin for chronic hepatitis C: systematic review of randomized trials. BMJ 2001; 323:1151-1155.
9. Manns MP, Wedemeyer H, Cornberg M: Treating viral hepatitis C: efficacy. side effects. and complications. Gut 2006; 55:1350-1359. (Pubitemid 44277369)
10. Fried MW, Shiffman ML, Reddy KR, et al: Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347:975-982.
11. Manns MP, McHutchison JG, Gordon SC, et al: Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial. Lancet 2001; 358:958-965.
12. Friedrich-Rust M, Zeuzem S, Sarrazin C: Current therapy for hepatitis C. Int J Colorectal Dis 2007; 22:341-349.
13. NICE 2006 - Peginterferon alpha and ribavirin for the treatment of mild chronic hepatitis C (extension of guidance 75); www.nice.org.
14. McHutchinson JC, Lawitz EJ, Shiftman ML, et al: Peginterferon Alfa-2b or Alfa-2a with Ribavirin for Treat ment of Hepatitis C Infection. N Engl J Med 2009; 361:580-593.
15. Ascione A, De Luca M, Tartaglione MT, et al: Peginterferon alpha-2a plus ribavirin versus peginterferon alpha-2b plus ribavirin in naive patients with chronic Hepatitis C virus infection: results of a prospective randomised trial. J Hepatology, 2008; 48:S370.
16. Witthoeft T, Hueppe D, John C: Efficacy and safety of peginterferon alfa-2a or -2b plus ribavirin in the routine daily treatment of Chronic Hepatitis C patients in Germany: the Practice study. J Hepatology, 2008; 48: S315.
17. Rumi MG, Aghemo A, Prati GM, et al: Randomized study comparing peginterferonalfa 2a plus ribavirin and peginterferonalfa 2b plus ribavirin in naïve patients with Chronic Hepatitis C: final results of the Milan Safety Tolerability (MIST) Study. Hepatology, 2008; 48:404A.
18. Craxi A, Piccinino F, Alberti A, et al: Predictors of SVR in naive HCV G1 patients in real life practice: the Probe. J. Hepatology, 2008; 48:S291.
19. Fattovich G, Guistina G, Degas F: Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterology 1997; 112:463-472.
20. Bennett WG, Inoue Y, Beck JR, et al: Estimates of the cost-effectiveness of a single course of interferon-alpha2b in patients with histologically mild chronic hepatitis C. Ann Intern Med 1997; 127:855-865.
21. Ascher NL, Lake JR, Emond J, Roberts J: Liver transplantation for hepatitis C virus-related cirrhosis. Hepatology 1994; 20:245-275.
22. Detre KM, Belle SH, Lomarddero M: Liver transplantation for chronic viral hepatitis. Viral Hepatitis Rev 1996; 2:219-228.
23. Kilpe VE, Krakauer H, Wren RE: An analysis of liver transplant experience from 37 transplant centers as reported to Medicare. Transplantation 1993; 56:554-561. (Pubitemid 23293014)
24. Kim WR, Poterucha JJ, Hermans JE, et al: Cost-effectiveness of 6 and 48 weeks of interferon-alpha therapy for chronic hepatitis C. Ann Intern Med 1997; 127:866-874.
25. Gines P, Quintero E, Arroyo V, et al. Compensated cirrhosis: natural history and prognostic factors. J Hepatology 1987; 7:122-128.
26. Tsukuma H, Hiyama T, Tanaka S, et al: Risk factors for hepatocellular carcinoma among patients with chronic liver disease. N Engl J Med 1993; 328:1797-1801. (Pubitemid 23174709)
27. Colombo M, De Franchis R, Del Ninno E, et al: Hepatocellular carcinoma in Italian patients with cirrhosis. N Engl J Med 1991; 325:675-680.
28. Dusheiko GM, Roberts JA: Treatment of chronic type B and C hepatitis with interferon alpha: an economic appraisal. Hepatology 1995; 22:1863-1873.
29. Ferenci P, Fried M.W, Shiffman ML, et al: Predicted sustained virological responses in chronic hepatitis C patients treated with pegitnerferon alfa-2a (40 KD) / ribavirin. Hepatology 2005; 43:425-433.
30. Davis GL, Wong JB, McHutchinson JG, et al: Early virological response to treatment with peginterferon alfa2b plus ribavirin in patients with chronic hepatitis C. Hepatology 2003; 38:645-652.
31. World Health Statistics 2008: http://apps.who.int/who-sis/database/life- tables/country data - year 2006.
32. Younossi ZM, Singer ME, McHutchinson JG, et al: Cost effectiveness of interferon alfa2b combined with ribavirin for the treatment of chronic hepatitis C. Hepatology 1999; 30:318-1324.
33. Grigorescu M: HCV Genotype 1 is Almost Exclusively Present in Romanian Patients with Chronic Hepatitis C; J Gastrointestin Liver Dis 2009; 18:45-50.
34. Yano M, Kumada H, Kage M, et al: The long-term pathological evolution of chronic hepatitis C. Hepatology 1996; 23:1334-1340.
35. CANAMED - National Catalogue for Drugs for 2009, www.msf-dgf.ro, accessed July 2009.
36. NICE - Guide to Technology appraisal process series. No. 5, 2001.
37. Sullivan SD, D. M. Jensen, D. E. Bernstein et al: Cost-Effectiveness of Combination Peginterferon α-2a and Ribavirin Compared With Interferon α-2b and Ribavirin in Patients With Chronic Hepatitis C. American Journal of Gastroenterology 2004; 99(8):1490-1496.